echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Use it with confidence!

    Ann Rheum Dis: Use it with confidence!

    • Last Update: 2022-05-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Baricitinib is an oral, reversible and selective Janus kinase (JAK)/JAK2 inhibitor indicated for the treatment of rheumatoid arthritis (RA)


    We summarized treatment-emergent adverse events in patients receiving any dose of baricitinib (All-bari-RA) from a comprehensive database (9 Phase III/II/Ib and 1 long-term extension)


     

    The included studies included 3770 patients who received baricitinib


    In conclusion, in this meta-analysis including long-term data on baricitinib in 3770 patients with active RA (median 4.


     

    Original source:

     

    Peter C Taylor, et al.


     



    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.